A comparative proteomic study identified LRPPRC and MCM7 as putative actors in imatinib mesylate cross-resistance in Lucena cell line

BACKGROUND: Although chronic myeloid leukemia (CML) treatment has improved since the introduction of imatinib mesylate (IM), cases of resistance have been reported. This resistance has been associated with the emergence of multidrug resistance (MDR) phenotype, as a BCR-ABL independent mechanism. The...

Descripción completa

Detalles Bibliográficos
Autores principales: Corrêa, Stephany, Pizzatti, Luciana, Du Rocher, Bárbara, Mencalha, André, Pinto, Daniela, Abdelhay, Eliana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3361502/
https://www.ncbi.nlm.nih.gov/pubmed/22458888
http://dx.doi.org/10.1186/1477-5956-10-23

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3361502/
https://www.ncbi.nlm.nih.gov/pubmed/22458888
http://dx.doi.org/10.1186/1477-5956-10-23

Ejemplares similares